110 מיליון דולר במימון כולל להאצת ההשקה המסחרית של ג'ניו בארה"ב

מונט-סן-גיבר, בלגיה – 10 ביוני 2026, GLOBE NEWSWIRE –

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), השלימה גיוס הון עצמי של 95 מיליון דולר וצופה קבלת נתח נוסף של 15 מיליון דולר מהלוואת הבנק האירופי להשקעות, המייצגת סך של 110 מיליון דולר בהון חדש. ציון דרך זה מסמן נקודת מפנה עבור Nyxoah, כאשר החברה נכנסת לשלב הבא של צמיחה ויצירת ערך ארוכת טווח המונעות על ידי ארה"ב.

$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch

Mont-Saint-Guibert, Belgium – June 10, 2026, GLOBE NEWSWIRE –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), has completed a $95 million equity financing and anticipates receipt of the $15 million second tranche of its European Investment Bank loan, which represents an aggregate of $110 million in new capital. This milestone marks a turning point for Nyxoah as the Company enters its next phase of U.S.-driven growth and long-term value creation.

Financing and Leadership Transition Highlights

• $110million in new capital
  • $95 million in equity financing with strong insider participation
  • $15 million anticipated second tranche of its European InvestmentBank loan by the end of June 2026
• Plannedacceleration of U.S. commercialization of Genio. Continued adoption ofGenio in the U.S. where the Company now has 40 sales reps in place underan experienced U.S.-based commercial leadership team

“This is a defining moment for Nyxoah,” said Olivier Taelman, Chief Executive Officer. “Building on the strong momentum of our first two commercial quarters in the U.S., this capital will allow Nyxoah to accelerate the commercial ramp of Genio in the United States and deliver on its mission for OSA patients.”

Robert Taub, Chairman of the Nyxoah Board, added: “The strong participation of both new and existing investors is a powerful endorsement of our Genio technology, our strategy and our team. With its financial foundation now secured, Nyxoah is well positioned to create long term value for shareholders.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:

Nyxoah

John Landry, CFO

[email protected]

Rémi Renard, Head of Investor Relations & Corporate Communication

[email protected]

Attachment

• ENGLISH_Summary Financing PR

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire